Endodiag develops non‑invasive diagnostic solutions for endometriosis, enabling healthcare professionals to detect the disease earlier through a blood test that measures disease‑specific biomarkers. By providing a reliable, surgery‑free diagnostic tool, the company aims to reduce the typical 7‑11‑year diagnosis delay, support personalized treatment planning, and improve fertility outcomes for the 10% of women affected by this often‑misdiagnosed condition.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Endometriosis is often misdiagnosed or undiagnosed for 7–11 years because definitive confirmation requires invasive surgery and histological analysis. This delay prevents timely treatment, increases disease progression, and reduces fertility prospects for women of reproductive age.
Solution
Endodiag is developing a non‑invasive blood test that detects disease‑specific biomarkers circulating in patients with endometriosis. The test provides clinicians with a reliable, early‑diagnostic tool that can be ordered in routine care settings, eliminating the need for surgical confirmation. In addition to detection, Endodiag offers a disease‑mapping platform that quantifies individual lesion burden and molecular characteristics, supporting personalized treatment and fertility planning. The biomarker data are processed with proprietary algorithms to generate a clinical report that integrates with existing workflows. By enabling earlier diagnosis and detailed disease profiling, Endodiag aims to reduce diagnostic delays, improve patient outcomes, and facilitate the development of targeted therapies.
Target Audience
Primary customers are gynecologists, reproductive endocrinologists, and fertility clinics that manage women of reproductive age presenting with chronic pelvic pain or infertility.
Features
- Blood‑based assay targeting a panel of validated endometriosis biomarkers
- Automated laboratory workflow compatible with standard clinical chemistry equipment
- Proprietary algorithm that translates biomarker levels into a quantitative disease‑severity score
- Disease‑mapping dashboard that visualizes lesion burden and molecular sub‑types for individualized treatment planning
- Clinical report format designed for integration with electronic health record systems
- Support for research collaborations to identify new therapeutic targets based on biomarker profiles